Generic Wegovy Weight Loss Injections Set to Flood UK Market
Cheap generic versions of the popular weight loss injection Wegovy are poised to become widely available in the United Kingdom within the coming months. This development follows the expiration of the patent for semaglutide, the key active ingredient in Wegovy and Ozempic, in several major manufacturing countries including India, China, and Brazil. Pharmaceutical companies in these nations are now rushing to produce and sell more affordable versions of the drug online, potentially making it accessible through unregulated channels.
Safety Warnings Over Unlicensed Online Sales
Members of Parliament have been issued stark warnings regarding the potential dangers of these unlicensed online pharmacies. There is significant concern that cheaper, appetite-suppressing drugs could be sold to individuals for whom they are not medically appropriate, such as young girls or people with conditions like anorexia. The Health and Social Care committee has urgently called for evidence from UK pharmacists and regulators, a move prompted by reported deaths linked to individuals purchasing these weekly injections on the black market.
Dr Kieran Seyan, Chief Medical Officer at Pharmacy2U, expressed his personal apprehension to the committee, stating, "My personal concern is that we have just seen semaglutide go off licence in places like India, so this is going to be manufactured on a wide scale. It's not that it's a dodgy drug but access to that illicit market may increase as a result."
Patent Expiry and Market Impact
Semaglutide, manufactured by pharmaceutical giant Novo Nordisk, is the core component of both Ozempic, prescribed on the NHS for Type 2 diabetes, and Wegovy, prescribed for weight management. The patent for this compound expired in India this month, triggering a major surge in production from local manufacturers. Industry reports indicate that more than fifty distinct brands are preparing to launch their own generic versions in the near future.
The patent is also set to expire in March 2026 in China and Brazil, with Turkey and South Africa following later this year. In contrast, patent protections are extended in the United States and Europe, where expiry is not anticipated until between 2031 and 2033. This disparity creates a window for generic products to enter less regulated markets.
John Spoors, Programme Director at the National Institute for Health and Care Excellence (NICE), informed the committee that a Government task force is actively investigating the potential impact of generic "biosimilar" weight loss jabs flooding the UK market. He noted, "When the patent expires, the prices start to drop."
Current Usage and Cost in the UK
Presently, an estimated 1.6 million Britons are using weight loss injections, predominantly obtained through private prescriptions. The NHS is gradually expanding access, but currently restricts it to patients with severe obesity and related health complications. The private cost for a four-week supply of Wegovy in the UK ranges significantly from approximately £80 to £300, depending on the required dosage.
Risks of the Illicit Market
The situation is exacerbated by the advertisement of unregulated "skinny jabs" on social media platforms like TikTok. Tragically, there have been fatalities linked to the use of unlicensed drugs, including a woman in her fifties from Sunderland in 2024. Committee chair Layla Moran highlighted the severity of the issue, stating, "We are way, way behind and there are a number of families and people who are now affected by this. Young girls are finding a way [to access the drugs]... they are getting it illegally from abroad. And some people have died. There is huge public concern about this."
Unregulated entities, including rogue beauty salons and online pharmacies, can sell these injections without conducting proper medical history checks. This poses serious risks, as the drugs may interact dangerously with pre-existing conditions or be administered to individuals who do not clinically require weight loss. Ms Moran added, "We've got millions of people who are eligible on the NHS, let alone those who are after it for a bikini body who shouldn't be taking it. They are turning to the black market to do it."
How the Drugs Work and Associated Dangers
Injections such as Ozempic, Wegovy, and Mounjaro function by mimicking a hormone called glucagon-like peptide 1 (GLP-1), which regulates hunger and feelings of fullness. They slow digestion and suppress appetite. Common side effects include vomiting, and they necessitate personalised support from medical specialists to ensure weight loss is sustained safely.
The illicit trade in these drugs is alarmingly lucrative. An investigator from the Medicines and Healthcare products Regulatory Agency (MHRA) revealed to MPs that the profit margins from trading these illicit jabs can surpass those of illegal drugs like cocaine and heroin.
Andy Morling, Head of Criminal Enforcement at the MHRA, provided a critical distinction: "We have seen GLP-1 drugs that are illegally traded but it is the genuine product. That doesn't make it safe. It hasn't been produced in accordance with genuine manufacturing processes, the sterility is questionable, or the dosage is questionable. It's absolutely not safe but it is the genuine product."
Mr Morling further cautioned about consumer awareness, noting, "I honestly believe that a lot of the people that are buying these products from the black market, don't know they're buying from the black market. There's been a blurring of the edges between medicine and cosmetic products over the last 18 months."
This convergence of patent expiry, aggressive generic manufacturing, and rampant online sales presents a complex public health challenge for UK authorities, balancing increased access against the paramount need for patient safety.
